2nd mRNA Process Development And Manufacturing Summit

The 2nd mRNA Process Development and Manufacturing Summit returns to Boston as the most comprehensive and technical industry dedicated forum, to address key industry bottlenecks from securing quality starting materials, quality by design and automated large-scale manufacturing, to ultimately reduce costs of mRNA production whilst harmonizing with regulatory expectations.

50+ world-class industry experts including leading mRNA players from Moderna, BioNTech, CureVac, Pfizer and more will take center stage across 3 jam-packed days, with 3 deep-dive content tracks on research scale, regulatory and clinical scale, and commercial scale covering key areas from plasmid DNA manufacturing, in vitro transcription, purification and mRNA drug product development to help accelerate your mRNA drugs into the clinic and through to market.

Join 250+ VPs, Directors and Heads of Process Development, Drug Substance, CMC, and MSAT at the world's only end-to-end meeting enabling scalable, cost-effective and commercially viable global mRNA production.

URLs:
Website: https://go.evvnt.com/1742633-0?pid=10018
Tickets: https://go.evvnt.com/1742633-2?pid=10018
Brochure: https://go.evvnt.com/1742633-3?pid=10018

Prices:
Drug Developer Pricing | Conference + Focus Day: USD 5396.00,
Drug Developer Pricing | Conference + Workshop Day : USD 5396.00,
Drug Developer Pricing | Conference Only: USD 3299.00,
Academic Pricing | Conference + Focus Day: USD 4696.00,
Academic Pricing | Conference + Workshop Day : USD 4696.00,
Academic Pricing | Conference Only: USD 2899.00,
Standard Pricing | Conference + Focus Day: USD 6396.00,
Standard Pricing | Conference + Workshop Day : USD 6396.00,
Standard Pricing | Conference Only: USD 3999.00

Speakers: Tingting Cui | Associate Director | AstraZeneca, Hui Zhi | Senior Scientist II | Beam Therapeutics, Andreas Kuhn | SVP - RNA Biochemistry and Manufacturing | BioNTech SE, Simon Unthan | Senior Director - RNA Manufacturing Technology Development and Automation | BioNTech SE, Anna Ernst | Associate Director - DNA Process Development | BioNTech SE, Lili Belcastro | Senior Principal Scientist | Bristol Myers Squibb, John Li | Director - Drug Substance | Capstan Therapeutics, Ramin Sabet-Azad | Chemistry, Manufacturing and Controls Lead | CEPI, Monica Dommel | Associate Director - Regulatory Affairs CMC | CureVac SE, John Zuris | Director - Editing Technologies | Editas Medicine, Nicole Ruggiero | Chief Executive Officer | EpiVax Therapeutics, Xinyue Zhang | Manager GeneLeap | Biotech (Luye Life Science), Nethaniah Dorh | Associate Director - Bioanalytical Development | GreenLight Biosciences, Stephen Kaba | Director - mRNA-Based Antigen Design | GreenLight BioSciences, Derek O'hagan | Senior Advisor - Vaccines Research and Development | GlaxoSmithKlineline, Danny Crawford | Director - Nucleic Acid Process Sciences | Intellia Therapeutics, Prakash Koodathingal | Director - RNA Therapeutics Development | Immunomic Therapeutics, Hang Yuan | CTO and Co-Founder | Innovac Therapeutics, Burak YILMAZ | Co-Founder and President | Kernal Biologics Inc., Harris Makatsoris | Professor - Manufacturing Systems | King's College London, Richard Braatz | Professor | Massachusetts Institute of Technology, Ike James | Head of Technology Transfer | Medicines Patent Pool, Antonio Grilo | Technology Transfer Expert | Medicines Patent Pool, Michael Homsy | Scientist | Merck and Co, Joshua McNeely | Senior Scientist - Vaccines Process Development | Merck and Co, Dipendra Gyawali | Senior Scientist and Team Lead - Process Development | Moderna, Joseph Schariter | Director - Process Development | Moderna, Sung-Hye Grieco | VP - Process Development and Program Management | Nutcracker Therapeutics, Harshal Zope | Director - Manufacturing Science and Technology | Orna Therapeutics, Bill Grier | Associate Director - Drug Substance and Process Development | Omega Therapeutics, Lakshmi Khandke | Senior Program Advisor | The PATH Malaria Vaccine Initiative, Aravindan Rajendran | Senior Principal Scientist - Group Leader | Pfizer, Mohamed ElSayed | EVP and CTO | RVAC Medicines, Chunghee Lee | Sr. Director | ReCode Therapeutics, Yimin Hua | Head of Biochemistry and Analytical Development; mRNA Center of Excellence | Sanofi, Hongyue Guo | Principal Scientist | Sanofi, Sujit Jain | Director - External Manufacturing | SalioGen Therapeutics, Craig Martin | Professor | University of Massachusetts Amherst, Zoltan Kis | Lecturer (Assistant Professor) | University of Sheffield, Jin Zhou | Executive Director - Technical Development; mRNA and Protein Biologics | Ultragenyx Pharmaceuticals, Vu Thai | Associate Director - Purification Process Development | Ultragenyx Pharmaceutical Inc, Vivian Chang | Associate Director - Upstream Process Development | Ultragenyx Pharmaceutical Inc, Gautam Sanyal | Principal Consultant | Vaccine Analytics LLC., Rajesh Beri | Principal Consultant | Vial 2 Vial Bio Solutions, Christopher Cheng | VP Process Development and RNA Technology | Verve Therapeutics, Patrick Arbuthnot | Personal Professor and Director | University of the Witwatersrand, Yasser Kehail | Business and Product Leader - mRNA CDMO Services | Aldevron, Aleš Štrancar | Executive Managing Director | BIA Separations, Scott Alderucci | Director - mRNA Process Development and GMP | Curia Global, Sudhakar | Voruganti Director | Pfanstiehl Inc, José Castillo | Chief Executive Officer | Quantoom Biosciences